http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 29 Oct 2024 08:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Press+Releases/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html <p class="bwalignc"> <i>Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities</i> </p> <p> NEW YORK--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fmedidata.com&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata&amp;index=1&amp;md5=0177f87e5f8ba1d95a947b55a8ead5ee" shape="rect">Medidata</a>, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, today announced a partnership with neuroscience solutions leader <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cogstate.com%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Cogstate&amp;index=2&amp;md5=b7b8f597a00ca4343b86506ab60061ab" shape="rect">Cogstate</a> to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others. </p><p> Together, the companies will deliver an improved experience, supported by <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.medidata.com%2Fen%2Fclinical-trial-products%2Fpatient-centric-clinical-trials%2Fecoa%2F&amp;esheet=54142421&amp;newsitemid=20241029570790&amp;lan=en-US&amp;anchor=Medidata+eCOA&amp;index=3&amp;md5=af2733bb696c4992556596b075dd71b8" http://www.streetinsider.com/Business+Wire/Medidata+and+Cogstate+Strike+Strategic+Partnership+Transforming+Clinical+Trials+in+Neurology+with+Clinical+Outcome+Assessment+%28eCOA%29+and+Clinician+Solutions+Powered+by+AI+and+Advanced+Analytics/23891389.html Tue, 29 Oct 2024 08:00:00 -0500 A.03272215 A.33811819 CGS DSY FR0014003T FR0014003T O.01130046 O.19615793 O.21898742 http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0500 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0500 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0500 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0500 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Press+Releases/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0500 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0500 A.40151759 CGS COGZF O.00050368 O.01130046 http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html <p>Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=9vEfcRyZkqBzxeQhO1r79EoteYm2NMh8XmKkYCS7K0rXBpPfB8f86HURIh_kx-_9dzuAUh2tvzUj1SfuuaUkgQ==" rel="nofollow" target="_blank">Cogstate</a>, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies.</p> <p>Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial http://www.streetinsider.com/Globe+Newswire/Cogstate+Expands+Alzheimer%26apos%3Bs+Disease+Leadership+with+Appointment+of+Dr.+Kaycee+Sink%2C+as+Chief+Medical+Officer/23832256.html Mon, 14 Oct 2024 11:14:00 -0500 A.40151759 CGS COGZF O.00050368 O.01130046